Temple University has named alumnus Devarshi Brahmbhatt to its “30 Under 30” list, recognizing his contributions in the pharmaceutical sector.
The annual list recognizes young alumni who have made remarkable contributions in their fields before the age of 30, celebrating innovation, and leadership.
Also read: Indian-Americans receive UT Dallas Distinguished Alumni Award
Brahmbhatt, who earned his MS in pharmaceutical sciences from Temple’s School of Pharmacy in 2018, has been acknowledged for his work in the biotech industry. With a career spanning research on vaccine development and gene therapy, he has established himself as a leader in global health innovation.
Brahmbhatt’s research focuses on developing advanced vaccines and therapies at the molecular level. His work includes creating more effective vaccines for infectious diseases like RSV and contributing to cell and gene therapy innovations, with the goal of addressing complex health challenges and improving patient outcomes globally.
During his early career at Calder Biosciences, a Brooklyn-based biotech startup, Brahmbhatt contributed to developing advanced vaccines for infectious diseases like RSV. In late 2024, he joined ProBio in New Jersey as a Scientist III, working on cutting-edge therapies for a range of human diseases.
Originally from Khambhat, India, Brahmbhatt came to Temple after being drawn to its pharmaceutical sciences program and the biotech hub of the Delaware Valley. Despite being initially rejected, he reapplied and was accepted, eventually finding mentorship and industry connections.
“Temple was a great opportunity that enabled me to connect to industry professionals and meet supportive professors who helped me secure a job in the biotech industry,” he said.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login